
News|Videos|April 8, 2026
Q1 2026 Recap: Gastroenterology News and Updates
Author(s)Abigail Brooks, MA
Fact checked by: Victoria Johnson
Q1 2026 GI updates include advances in IBD and IBS therapies, long-term data, and new insights into access challenges for younger patients.
Advertisement
Advertisement
The first quarter of 2026 delivered a steady stream of meaningful updates in gastroenterology, with advances spanning irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and real-world insights into treatment access and durability. Across clinical trials and observational research, the field continues to move toward more personalized, evidence-driven care while also grappling with persistent gaps in access and affordability.
Related to this article

Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.
Advertisement
Advertisement

